naloxone for opioid safety by phillip coffin, md, mia
TRANSCRIPT
![Page 1: Naloxone for Opioid Safety by Phillip Coffin, MD, MIA](https://reader036.vdocument.in/reader036/viewer/2022070511/589ffeef1a28abd40b8b48b3/html5/thumbnails/1.jpg)
Naloxone for Opioid Safety
Phillip O Coffin MD MIASan Francisco Department of Public Health
University of California San Francisco
![Page 2: Naloxone for Opioid Safety by Phillip Coffin, MD, MIA](https://reader036.vdocument.in/reader036/viewer/2022070511/589ffeef1a28abd40b8b48b3/html5/thumbnails/2.jpg)
Disclosures
• No financial disclosures
![Page 3: Naloxone for Opioid Safety by Phillip Coffin, MD, MIA](https://reader036.vdocument.in/reader036/viewer/2022070511/589ffeef1a28abd40b8b48b3/html5/thumbnails/3.jpg)
Oxycontin
Dilaudid/ Duragesic
Kadian
Norco
Atiq
HMO enrollment >80 million
FDA lifts rules on Direct-to-Consumer advertising
Welfare reform
State law/boards liberalize opioids for chronic pain
JCAHO 5th Vital Sign
Fentora
Subsys
Abstral
Roxicodone
Embeda Exalgo
Acuroxgeneric morphinesPalladone
Avinza
generic hydrocodone
generic fentanyl lozenge
generic oxycodones
Opana
Opana ER
Dilaudid (lower dose)
Onsolis
Lazanda
Oxecta Zohydro
Hysingla
generic oxymorphone Targiniq
CDC reports rising Rx deaths
Policy and practice changes to reduce OA prescribing begin
19951990
![Page 4: Naloxone for Opioid Safety by Phillip Coffin, MD, MIA](https://reader036.vdocument.in/reader036/viewer/2022070511/589ffeef1a28abd40b8b48b3/html5/thumbnails/4.jpg)
![Page 5: Naloxone for Opioid Safety by Phillip Coffin, MD, MIA](https://reader036.vdocument.in/reader036/viewer/2022070511/589ffeef1a28abd40b8b48b3/html5/thumbnails/5.jpg)
Naloxone Timeline
![Page 6: Naloxone for Opioid Safety by Phillip Coffin, MD, MIA](https://reader036.vdocument.in/reader036/viewer/2022070511/589ffeef1a28abd40b8b48b3/html5/thumbnails/6.jpg)
Naloxone Programs and OD Rate, 2010
![Page 7: Naloxone for Opioid Safety by Phillip Coffin, MD, MIA](https://reader036.vdocument.in/reader036/viewer/2022070511/589ffeef1a28abd40b8b48b3/html5/thumbnails/7.jpg)
Naloxone Programs and OD Rate, 2014Number* and location of local drug overdose prevention programs providing naloxone to laypersons, as of
June 2014, and age-adjusted rates† of drug overdose deaths§ in 2013 — United States
* Total N = 644; numbers on map indicate the total number of programs within each state.† Per 100,000 population.
§ CDC, National Center for Health Statistics; Compressed Mortality File 1999–2013 on CDC WONDER Online Database, released January 2015.
![Page 8: Naloxone for Opioid Safety by Phillip Coffin, MD, MIA](https://reader036.vdocument.in/reader036/viewer/2022070511/589ffeef1a28abd40b8b48b3/html5/thumbnails/8.jpg)
Naloxone Effectiveness
(10) Walley et al., BMJ 2013(13) Davidson et al., Naloxone distribution to drug users in California, unpublished data
![Page 9: Naloxone for Opioid Safety by Phillip Coffin, MD, MIA](https://reader036.vdocument.in/reader036/viewer/2022070511/589ffeef1a28abd40b8b48b3/html5/thumbnails/9.jpg)
Needle Atomizer / as-sembly
Expensive High dose?
![Page 10: Naloxone for Opioid Safety by Phillip Coffin, MD, MIA](https://reader036.vdocument.in/reader036/viewer/2022070511/589ffeef1a28abd40b8b48b3/html5/thumbnails/10.jpg)
![Page 11: Naloxone for Opioid Safety by Phillip Coffin, MD, MIA](https://reader036.vdocument.in/reader036/viewer/2022070511/589ffeef1a28abd40b8b48b3/html5/thumbnails/11.jpg)
Hero
in O
verd
ose
Deat
hs: S
F 19
97-1
999
![Page 12: Naloxone for Opioid Safety by Phillip Coffin, MD, MIA](https://reader036.vdocument.in/reader036/viewer/2022070511/589ffeef1a28abd40b8b48b3/html5/thumbnails/12.jpg)
Naloxone Distribution & Heroin Deaths in San Francisco
2000 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 20140
200
400
600
800
1000
1200
0
20
40
60
80
100
120
140
160
New Enrollments
Reversals
Heroin deaths (no 2013/14 data)
Naloxone distribution begins, 2003
? ?
![Page 13: Naloxone for Opioid Safety by Phillip Coffin, MD, MIA](https://reader036.vdocument.in/reader036/viewer/2022070511/589ffeef1a28abd40b8b48b3/html5/thumbnails/13.jpg)
Census tracts near DOPE sites
Naloxone Sites and Reversals 2010-2012
![Page 14: Naloxone for Opioid Safety by Phillip Coffin, MD, MIA](https://reader036.vdocument.in/reader036/viewer/2022070511/589ffeef1a28abd40b8b48b3/html5/thumbnails/14.jpg)
• 9% involved heroin
• Primary care data accessible for 50% of decedents, 80%
of whom were prescribed opioids
Census tracts near DOPE sites
Opioid Overdose Deaths 2010-2012
![Page 15: Naloxone for Opioid Safety by Phillip Coffin, MD, MIA](https://reader036.vdocument.in/reader036/viewer/2022070511/589ffeef1a28abd40b8b48b3/html5/thumbnails/15.jpg)
• 6 safety net clinics
• Staff trained
• Atomizer/brochure in ziplock bag
• IM or IN naloxone prescribed (covered by all public insurance)
• Pharmacists trained as needed
Clinical Program
![Page 16: Naloxone for Opioid Safety by Phillip Coffin, MD, MIA](https://reader036.vdocument.in/reader036/viewer/2022070511/589ffeef1a28abd40b8b48b3/html5/thumbnails/16.jpg)
All Patients Using Opioids Chronically
Risk-Stratification
Simple to remember Less costlyClinicians are poor at predicting risk Potentially less work for clinician / clinic
Risks are based on retrospective data analyses
Patients do not perceive a risk of “overdose” from prescribed medications1
~40% of deaths result from diverted medications2; co-prescribed naloxone
may go with the opioids
1) Coffin PO, unpublished data; 2) Hirsch A, Proescholdbell SK, Bronson W, Dasgupta N. Prescrip-tion histories and dose strengths associated with overdose deaths. Pain Med. 2014;15(7):1187-95.
![Page 17: Naloxone for Opioid Safety by Phillip Coffin, MD, MIA](https://reader036.vdocument.in/reader036/viewer/2022070511/589ffeef1a28abd40b8b48b3/html5/thumbnails/17.jpg)
![Page 18: Naloxone for Opioid Safety by Phillip Coffin, MD, MIA](https://reader036.vdocument.in/reader036/viewer/2022070511/589ffeef1a28abd40b8b48b3/html5/thumbnails/18.jpg)
Provider Themes Regarding Naloxone PrescribingStrengthen patient/provider relationship
• “The ability to prescribe naloxone has been the most positive change to our management of chronic pain.”
Leads to more open discussion about opioids
• “[Naloxone] has allowed me to … keep them engaged in care … and has opened up conversations about substance use treatment options.”
![Page 19: Naloxone for Opioid Safety by Phillip Coffin, MD, MIA](https://reader036.vdocument.in/reader036/viewer/2022070511/589ffeef1a28abd40b8b48b3/html5/thumbnails/19.jpg)
Patient Themes Regarding Naloxone (N=60)Frustration:
• “It felt like they think I’m gonna overdose…I don’t think I’m gonna overdose on something that’s prescribed”
Appreciation:
• “I felt great. I felt like she really cared about me.”
Community benefits:
• “I wasn’t sure if I’d ever use it. But on the other hand, because I live in the tenderloin … it might be a good thing to have with me.”
More cautious with opioids:
• “I’ve probably been a little more cautious. Just being careful to take the right amount, count the hours, you know, just thinking more cautiously about dosing.”
![Page 20: Naloxone for Opioid Safety by Phillip Coffin, MD, MIA](https://reader036.vdocument.in/reader036/viewer/2022070511/589ffeef1a28abd40b8b48b3/html5/thumbnails/20.jpg)
Opioid Refugees
?
![Page 21: Naloxone for Opioid Safety by Phillip Coffin, MD, MIA](https://reader036.vdocument.in/reader036/viewer/2022070511/589ffeef1a28abd40b8b48b3/html5/thumbnails/21.jpg)
Opioid Safety Initiatives
Reduce morbidity
& mortality
![Page 22: Naloxone for Opioid Safety by Phillip Coffin, MD, MIA](https://reader036.vdocument.in/reader036/viewer/2022070511/589ffeef1a28abd40b8b48b3/html5/thumbnails/22.jpg)
Opioid Safety Initiatives
Reduce morbidity
& mortality
Modify prescribing
practice• Staged treatment
(FDA relabeling)• Med
reconciliation• Risk factor
screens• Dose limits
Reduce diversion
•PDMP•Pharmacy
reviews•Take-back programs
•Pain Agreements
•Abuse deterrents
![Page 23: Naloxone for Opioid Safety by Phillip Coffin, MD, MIA](https://reader036.vdocument.in/reader036/viewer/2022070511/589ffeef1a28abd40b8b48b3/html5/thumbnails/23.jpg)
Opioid Safety Initiatives
Reduce morbidity
& mortality
Modify prescribing
practice• Staged treatment
(FDA relabeling)• Med
reconciliation• Risk factor
screens• Dose limits
Reduce diversion
•PDMP•Pharmacy
reviews•Take-back programs
•Pain Agreements
•Abuse deterrents
Expand non-opioid pain
management• PT/OT
• Behavioral therapy
• Acupuncture• Massage
• Non-opioid medications
![Page 24: Naloxone for Opioid Safety by Phillip Coffin, MD, MIA](https://reader036.vdocument.in/reader036/viewer/2022070511/589ffeef1a28abd40b8b48b3/html5/thumbnails/24.jpg)
Opioid Safety Initiatives
Reduce morbidity
& mortality
Modify prescribing
practice• Staged treatment
(FDA relabeling)• Med
reconciliation• Risk factor
screens• Dose limits
Reduce diversion
•PDMP•Pharmacy
reviews•Take-back programs
•Pain Agreements
•Abuse deterrents
Manage substance use• Opioid agonist
treatments• Good Sam laws• Comorbid SUD
treatment• Other harm
reduction services
Expand non-opioid pain
management• PT/OT
• Behavioral therapy
• Acupuncture• Massage
• Non-opioid medications
![Page 25: Naloxone for Opioid Safety by Phillip Coffin, MD, MIA](https://reader036.vdocument.in/reader036/viewer/2022070511/589ffeef1a28abd40b8b48b3/html5/thumbnails/25.jpg)
Opioid Safety Initiatives
Reduce morbidity
& mortality- Naloxone
Modify prescribing
practice• Staged treatment
(FDA relabeling)• Med
reconciliation• Risk factor
screens• Dose limits
Reduce diversion
•PDMP•Pharmacy
reviews•Take-back programs
•Pain Agreements
•Abuse deterrents
Manage substance use• Opioid agonist
treatments• Good Sam laws• Comorbid SUD
treatment• Other harm
reduction services
Expand non-opioid pain
management• PT/OT
• Behavioral therapy
• Acupuncture• Massage
• Non-opioid medications
![Page 26: Naloxone for Opioid Safety by Phillip Coffin, MD, MIA](https://reader036.vdocument.in/reader036/viewer/2022070511/589ffeef1a28abd40b8b48b3/html5/thumbnails/26.jpg)
Opioid Stewardship and Naloxone
Prescribing restrictions
initiated
Naloxone distribution
initiated
Trends in opiate-related deaths in Multnomah County, 2014
![Page 27: Naloxone for Opioid Safety by Phillip Coffin, MD, MIA](https://reader036.vdocument.in/reader036/viewer/2022070511/589ffeef1a28abd40b8b48b3/html5/thumbnails/27.jpg)
![Page 28: Naloxone for Opioid Safety by Phillip Coffin, MD, MIA](https://reader036.vdocument.in/reader036/viewer/2022070511/589ffeef1a28abd40b8b48b3/html5/thumbnails/28.jpg)
Inevitable
Pre-ventable
![Page 30: Naloxone for Opioid Safety by Phillip Coffin, MD, MIA](https://reader036.vdocument.in/reader036/viewer/2022070511/589ffeef1a28abd40b8b48b3/html5/thumbnails/30.jpg)
Acknowledgments• Funding from:
• NIDA R21DA036776• NIDA R03DA038084• California Healthcare Foundation
• The many people lost to overdose and those who have helped save a life